CHMFL-48

CHMFL-48 is an orally active BCR-ABL kinase inhibitor targeting both wild-type (wt) and various imatinib-resistant mutants. The IC50 values for CHMFL-48 against ABL wild-type and ABL T315I mutant are 1 nM and 0.8 nM, respectively. CHMFL-48 exerts its effects by blocking the autophosphorylation of BCR-ABL wild-type and mutant forms, which impacts downstream signaling mediators such as STAT5 and CRKL, leading to cell cycle arrest and induction of apoptosis. CHMFL-48 holds potential for research into chronic myeloid leukemia (CML) [1].

Product Specifications

CAS Number

[2479290-65-6]

UNSPSC

12352005

Target

Apoptosis; Bcr-Abl; STAT

Type

Reference compound

Related Pathways

Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/chmfl-48.html

Smiles

CC1=C(N2C=C(C3=CN=C(NC=C4)C4=C3)C=N2)C=C(NC(C5=CC=C(CN6CCN(C)CC6)C(C(F)(F)F)=C5)=O)C=C1

Molecular Formula

C31H30F3N7O

Molecular Weight

573.61

References & Citations

[1]Lu T, et al. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML) . Eur J Pharmacol. 2021 Apr 15;897:173944.